Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

AstraZeneca PLC (LSE:AZN) Gears Up for Q3 Results on Friday as FTSE 100's Largest Company Faces Pharma Jitters

AstraZeneca PLC (LSE:AZN), the UK's largest listed company by market value, is in focus on 28 October 2026 as investors prepare for its nine-month and third-quarter results on Friday 30 October. The update arrives just two days after GSK fell about 4.8% on disappointing …

Ankur Sharma | 29 October 2026

GSK plc (LSE:GSK) Drops Nearly 5% on FTSE 100 as Vaccine Sales Dip Overshadows Q3 Beat

GSK plc (LSE:GSK) was one of the heaviest drags on the FTSE 100 on 28 October 2026 after its third-quarter update. The shares fell sharply in early trading and closed around 4.8% lower, even though headline revenue edged past market expectations and management kept …

Ankur Sharma | 29 October 2026

Haleon PLC (LSE:HLN) Braces for Q3 Trading Statement as FTSE 100 Consumer Health Group Tests 2026 Growth Target

Haleon PLC (LSE:HLN), the consumer healthcare group behind Sensodyne, Panadol, Centrum and Voltaren, is in focus on 28 October 2026 as investors prepare for its third-quarter trading statement on Thursday 29 October. The update arrives a day after GSK, its former parent, fell about …

Ankur Sharma | 29 October 2026

GSK plc (LSE:GSK): Why This FTSE 100 Stock Is in Focus on 28 October 2026 and What Comes Next

• GSK plc (LSE:GSK) is being assessed against third-quarter results, pipeline spending and margin outlook.

Ankur Sharma | 28 October 2026

Oxford Biomedica (LSE:OXB): Why the FTSE 250 Stock Is in Focus and What Investors Watch Next

Oxford Biomedica operates through cell and gene therapy contract development and manufacturing. The investment case depends on the economic quality of these activities rather than headline activity alone. Investors typically assess pricing power, customer concentration, repeat business, capital requirements and the stability of cash …

Ankur Sharma | 28 October 2026

Cardiogeni (CGNI): The Fresh UK Market Signal Investors Should Not Overlook

Cardiogeni is included in this second batch of UK-listed company coverage for 28 October 2026 after a fresh corporate disclosure brought a new point for investors to assess. The relevant ticker format is LSE:CGNI. The company is considered here in the context of the …

Ankur Sharma | 28 October 2026

GSK Shares in Focus After Q3: Can Specialty Medicines Offset Vaccine Weakness?

GSK is in focus on 28 October 2026 after its latest company update put the market is weighing strong specialty-medicine momentum against uneven vaccine demand and the ability of the pipeline to sustain growth as products mature at the centre of the conversation. The …

Ankur Sharma | 28 October 2026

Ondine Biomedical’s Safety Update Puts Clinical Evidence and Commercial Adoption in Focus

Ondine Biomedical is in focus on 28 October 2026 after its latest company update put investors will look for the size and design of the study, safety details, clinical relevance, regulatory implications and the next milestones at the centre of the conversation. The company …

Ankur Sharma | 28 October 2026

Aptamer Group: partnerships must convert into repeatable commercial revenue (LSE:APTA)

As of 28 October 2026, Aptamer Group plc (LSE:APTA) is drawing attention for a question that matters to shareholders: whether its current operational, commercial or project milestones can translate into durable value. The company trades on the London Stock Exchange’s AIM market, where smaller …

Ankur Sharma | 28 October 2026

Cambridge Nutritional Sciences reaches AGM day with adoption and revenue quality in focus (LSE:CNSL)

As of 28 October 2026, Cambridge Nutritional Sciences PLC (LSE:CNSL) is drawing attention for a question that matters to shareholders: whether its current operational, commercial or project milestones can translate into durable value. The company trades on the London Stock Exchange’s AIM market, where …

Ankur Sharma | 28 October 2026
Support

Hi! How can we help you today?

Loading…